Clinical Trial

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Study acronym: REACT-AF
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Protocol Amendment History 64 amendments
This ClinicalTrials.gov record has been amended 64 times since 2023-04-19; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2023-07-21
Trial Details
NCT Number NCT05836987
Lead Sponsor Johns Hopkins University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Northwestern University
Conditions Atrial Fibrillation
Enrollment 5,350 participants
Start Date 2023-07-13
Primary Completion 2029-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09